Evaxion A/S American Depositary Share (EVAX) is a publicly traded Healthcare sector company. As of May 21, 2026, EVAX trades at $3.79 with a market cap of $34.11M and a P/E ratio of 0.00. EVAX moved +0.00% today. Year to date, EVAX is -16.67%; over the trailing twelve months it is +128.57%. Its 52-week range spans $1.20 to $16.10. Analyst consensus is strong buy with an average price target of $11.25. Rallies surfaces EVAX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Evaxion’s AI Platform Hits 86% Precision, Extends Phase 2 Trial and Secures Cash into H2 2027: Evaxion’s AI-Immunology™ achieved 86% vaccine target recognition for cancer vaccine EVX-01, enabling presentation of three-year phase 2 data in H2 2026. It completed one-year extension of EVX-01 trial, unveiled AI-driven polio vaccine concepts with Gates Foundation, promoted Birgitte Rønø to CSO/COO and secured cash runway into H2 2027.
| Metric | Value |
|---|---|
| Price | $3.79 |
| Market Cap | $34.11M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $16.10 |
| 52-Week Low | $1.20 |
| Volume | 20 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
4 analysts cover EVAX: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $11.25.